CTT Cancer Targeting Technologies Ltd

CTT Cancer Targeting Technologies is a biopharmaceutical company focusing on oncology and inflammatory diseases. The company possesses two core technologies: the phage-display technology and the peptide-liposome technology. The combination of these two will generate a steady flow of objects to be further developed into new drug delivery systems and diagnostic imaging tools. The company was founded in 2001 after CTT Cancer Targeting Technologies team had won the first prize in 2001 Venture Cup Finland contest, and the second place in the Munich Entrepreneurship Competition European Workshop MECEW 2001. In 2005, the company received an honorable mention as one of the most successful start-up companies rewarded in Venture Cup during 2000-2004.